Intravenous Transplantation of Allograft hUC-MSC was More Effective Than Subarachnoid Transplantation of BM-MSCs in Patients with Parkinson's Syndrome and Secondary Parkinson's Syndrome
Wenting Wang,Ping Gu,Fu-Cheng Qiu,Li-Na Zhang,Zhong-Xia Zhang,Bingchuan Xie,Ci Dong,Rui Han,Hui-Miao Liu,Bao-Yong Yan
DOI: https://doi.org/10.1166/jbt.2016.1425
2016-01-01
Journal of Biomaterials and Tissue Engineering
Abstract:Objective: Comparative analysis the effects of subarachnoid transplantation of autologous bone marrow mesenchymal stem cells (BM-MSC) and intravenous transplantation of allograft human umbilical cord mesenchymal stem cells (hUC-MSC) on patients with Parkinson's syndrome (PS). Methods: Patients with PS who had been definitely diagnosed and hospitalized, either subarachnoid transplantation of autologous BM-MSC or intravenous transplantation of allograft hUC-MSC, were included in our hospital. Patients were graded according to the following scales prior to and three months after transplantation: (1) Unified Parkinson's Disease Rating Scale (UPDRS); (2) International Cooperative Ataxia Rating Scale (ICARS); (3) Activities of Daily Living Scale (ADL); (4) Mini-mental state examination (MMSE); (5) Hamilton Depression Scale 24 Item (HAMD(24)) and Hamilton Anxiety Scale 14 Item (HAMA(14)) to evaluate the symptoms of PS, degree of ataxia, quality of life, cognitive functions and emotional changes. Results: BM-MSC transplantation was performed in seven patients, four of which significantly improved, 2 patients improved slightly, and one had no improvement. The group receiving hUC-MSCs included 5 patients, 3 of which significantly improved, 1 was slightly improved and one had no improvement. Comparing the symptoms before and three months after transplantation, we observed that the UPDRS total score, UPDRSII, UPDRSIII, ICARS scores of gait, cooperative ataxia, dysarthrosis were significantly decreased (P < 0.05), and ADL scores were significantly increased (P < 0.05) in both groups. Most importantly, the hUC-MSC group showed improvements in the scores of UPDRSI, HAMA(14) and HAMD(24), the ICARS scores of ocular duskiness were significantly decreased (all P < 0.05), while the MMSE score was significantly increased (P < 0.05). However, these scores were not significantly changed in the BM-MSC group. Conclusion: The clinical symptoms (ataxia, language and swallowing) of PS patients were improved in both subarachnoid transplantation of autologous BM-MSC and intravenous transplantation of allograft hUC-MSC. The hUC-MSC transplantation, but not BM-MSC transplantation, significantly improved the cognition and emotional function of these patients.